Evidence map›Paper›PMID 35142953›Full record

ArticleWiener medizinische Wochenschrift (1946)2022

Natalizumab treatment during pregnancy in multiple sclerosis-clinical and bioethical aspects of an ongoing debate.

Klaus Berek, Claudia Paganini, Harald Hegen, Gabriel Bsteh, Astrid Grams, Michael Auer, Thomas Berger, Florian Deisenhammer, Franziska Di Pauli

Abstract readCase Reports
PubMed Publisher
In one paragraph

Article in Wiener medizinische Wochenschrift (1946), 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.3field-weighted citation impact, top 47% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 2 citations in OpenAlex.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 3 institutions in 1 country.

Klaus BerekDepartmentof Neurology, Medical University of Innsbruck, Innsbruck, Austria.
Claudia PaganiniDepartment of Christian Philosophy, University of Innsbruck, Innsbruck, Austria.
Harald HegenDepartmentof Neurology, Medical University of Innsbruck, Innsbruck, Austria.
Gabriel BstehDepartment of Neurology, Medical University of Vienna, Vienna, Austria.
Astrid GramsDepartment of Neuroradiology, Medical University of Innsbruck, Innsbruck, Austria.
Michael AuerDepartmentof Neurology, Medical University of Innsbruck, Innsbruck, Austria.
Thomas BergerDepartment of Neurology, Medical University of Vienna, Vienna, Austria.
Florian DeisenhammerDepartmentof Neurology, Medical University of Innsbruck, Innsbruck, Austria.
Franziska Di PauliDepartmentof Neurology, Medical University of Innsbruck, Innsbruck, Austria. franziska.di-pauli@tirol-kliniken.at.
Universität Innsbruck · ATInnsbruck Medical University · ATMedical University of Vienna · AT

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundNatalizumab is an approved treatment for relapsing remitting multiple sclerosis; however, its safety during pregnancy is not formally proven. CASE PRESENTATION: We report a woman with multiple sclerosis being treated with natalizumab before pregnancy. After withdrawal of natalizumab, she suffered a severe, disabling rebound. In agreement with the patient, natalizumab was restarted during pregnancy. Our patient improved substantially and gave birth to a healthy boy.

conclusionUse of natalizumab during pregnancy may be an option in highly active multiple sclerosis.

Indexed as

Multiple SclerosisMultiple Sclerosis, Relapsing-RemittingFemaleHumansImmunologic FactorsMaleNatalizumabPregnancyImmunologic FactorsNatalizumabBioethicsDecision-makingDisease-modifying treatmentMSSafety

Identifiers

PMID35142953
OpenAlexW4211090882

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.